AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12067330
Drug: IgM anti-GM1
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IgM anti-GM1 antibodies in normal controls (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)
Trial: 19794979
Drug: C1 inhibitor
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1 inhibitor
Trial: 26407698
Drug: 25 %
RxNorm normalized name: oxygen 25 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Trial: 15202814
Drug: Extended daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended daily dialysis (EDD)
Trial: 11840808
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg capoten at 10.00
Trial: 11840808
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg capoten at 13.00
Trial: 11840808
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg capoten at other hours (7.00, 16.00, 19.00, 22.00)
Trial: 9949668
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg daily, increasing to 2-3 tablets based on metabolic control)
Trial: 7815986
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli preparation (Mutaflor)
Trial: 31761120
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for dust mite
Trial: 31761120
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for latex
Trial: 31761120
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for venom hypersensitivity
Trial: 25925891
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of abiraterone acetate plus prednisone (AA + P)
Trial: 23557454
Drug: Empowering program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empowering program (twice a week for 60 minutes over 6 weeks)
Trial: 19689759
Drug: State-of-the-art conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-of-the-art conservative treatment
Trial: 28090679
Drug: Prucalopride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (2 mg/day)
Trial: 24183868
Drug: Postoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative concurrent radiochemotherapy (POCRT) with paclitaxel (175 mg/m²) and cisplatin (60 mg/m²) for four cycles, plus radiotherapy (50.4 Gy/28 fractions) concurrently with the first 2 cycles of chemotherapy.
Trial: 24183868
Drug: Postoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative concurrent radiochemotherapy (POCRT) for patients with ≥2 pN2 lymph nodes.
Trial: 21853265
Drug: Synbiotic dietary
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic dietary supplement (Lactobacillus acidophilus NCFM and lactitol, 10 g lactitol and 2×10^10 cells of probiotic bacteria, taken twice a day for 2 weeks)
Trial: 30762770
Drug: Sham-acupoints acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-acupoints acupuncture and antidepressant (fluoxetine hydrochloride tablets)
Trial: 25041619
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with compression therapy
Trial: 15283821
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg x kg(‐1) rocuronium (group I)
Trial: 15283821
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg x kg(‐1) rocuronium (group II)
Trial: 3429698
Drug: Itazigrel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itazigrel (25 mg each morning for five doses)
Trial: 17347074
Drug: Metoprolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (5 mg administered via venous cannula)
Trial: 17347074
Drug: Diltiazem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (25 mg administered via venous cannula)
Trial: 11871368
Drug: Red palm
RxNorm normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red palm oil (5 ml)
Trial: 7408393
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin intravenously
Trial: 436626
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg digoxin intravenously
Trial: 7408393
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg digoxin intravenously
Trial: 7408393
Drug: Single-dose kinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose kinetics
Trial: 30702059
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (765 mg)
Trial: 28152319
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant supplementation (Squalene 100 mg, Vitamin C 30 mg, Coenzyme Q10 10 mg, Zinc 5 mg, Beta Carotene 3.6 mg, Bioflavonoids 30 mg, Selenium 55 mcg) administered daily for 2 weeks
Trial: 25749317
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A intake in hypertensive subpopulation (1732.77±962.27 µg)
Trial: 25749317
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D intake in hypertensive subpopulation (8.13±9.71 µg)
Trial: 25749317
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E intake in hypertensive subpopulation (18.79±7.84 mg)
Trial: 26693033
Drug: Desvenlafaxine 50
RxNorm normalized name: desvenlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 50 mg/d
Trial: 11515850
Drug: Prolonged-release granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release granules (1 packet four times daily)
Trial: 11515850
Drug: Prolonged-release tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tablets (2 tablets four times daily)
Trial: 9935253
Drug: Treatment D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment D: two crushed 100-mg trovafloxacin tablets suspended in water and given through a nasogastric tube into the stomach with enteral feeding solution
Trial: 8118758
Drug: Sustained-release monofluorophosphate
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release monofluorophosphate (MFP-SR) 76 mg
Trial: 8118758
Drug: Plain monofluorophosphate
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain monofluorophosphate (MFP) 76 mg
Trial: 17237315
Drug: Isolated isoflavone
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated isoflavone supplementation (84 mg/d)
Trial: 1750594
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (patient-controlled analgesia)
Trial: 10928578
Drug: Gabapentin 1800
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1800 mg per day
Trial: 1569453
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous methotrexate (HD; 4 g/m2)
Trial: 1569453
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intravenous methotrexate (LD; 40 mg/m2)
Trial: 3839174
Drug: morphine (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (0.125 mg/kg)
Trial: 31997237
Drug: Qixiong Zhongzi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qixiong Zhongzi Decoction (QZD) 150 mL twice a day for 12 weeks
Trial: 31997237
Drug: Levocarnitine oral
RxNorm normalized name: levocarnitine Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine oral liquid 1 g twice a day for 12 weeks
Trial: 31997237
Drug: Levocarnitine oral
RxNorm normalized name: levocarnitine Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine oral liquid
Trial: 22052304
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with diode laser for the first two sessions and alexandrite laser for the next two sessions
Trial: 22052304
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with diode and alexandrite lasers
Trial: 19380259
Drug: Cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping therapy (wet cupping), single application
Trial: 9277426
Drug: Liquid distension
RxNorm normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid distension (100 ml)
Trial: 10220634
Drug: Felodipine-metoprolol 10/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-metoprolol 10/100 mg
Trial: 1303482
Drug: Felodipine 10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 10 mg
Trial: 7783459
Drug: Composite acupuncture
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite acupuncture treatment (acupuncture, auriculo‐acupoint pellet pressure, herbal plasters)
Trial: 19244883
Drug: GTRF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTRF treatment (bioabsorbable membrane and demineralized xenograft)
Trial: 19244883
Drug: CAF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF treatment (control)
Trial: 16652135
Drug: oral freeze-dried
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral freeze-dried NT 6 gm/day
Trial: 8925352
Drug: Low-dose depot
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose depot haloperidol (25 mg) combined with targeted oral neuroleptics
Trial: 28160351
Drug: Lithium monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium monotherapy
Trial: 31757519
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine lozenge used 15 minutes before cue exposure
Trial: 29145890
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg metolazone single dose
Trial: 29145890
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg metolazone multiple doses
Trial: 29145890
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg metolazone with food effect
Trial: 29145890
Drug: Metolazone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone (all doses)
Trial: 26717214
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait therapy with the Lokomat® system
Trial: 12816549
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg/day) + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Trial: 12816549
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Trial: 9185746
Drug: Low-dose MEG-X
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MEG-X test (50 mg lidocaine intravenously)
Trial: 2866788
Drug: Azepexole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azepexole 10 mg
Trial: 31119206
Drug: O6-PUFA (soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O6-PUFA (soybean oil, 6 g/d)
Trial: 31119206
Drug: O3-PUFA (fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O3-PUFA (fish oil, 6 g/d)
Trial: 17225706
Drug: Leukotriene inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene inhibitors
Trial: 21818628
Drug: Galantamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine treatment
Trial: 19884223
Drug: Therapist-led group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-led group treatment
Trial: 18299490
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both traditional decision aid and chronic disease trajectory model
Trial: 17312857
Drug: Polypeptide-based heparin-bonded
RxNorm normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypeptide-based heparin-bonded circuits with reduced heparinization
Trial: 22817699
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol
Trial: 30950894
Drug: Cyclotorsion compensated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclotorsion compensated SMILE surgery (CC group: 54 eyes)
Trial: 28385705
Drug: 3-year specialised
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-year specialised treatment (extended early intervention)
Trial: 25823909
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml 0.5% silver nitrate
Trial: 25823909
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml 0.3% silver nitrate
Trial: 23097311
Drug: SC abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC abatacept (125 mg/week) with methotrexate (combination)
Trial: 23097311
Drug: Long-term extension
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term extension (LTE) with SC abatacept without methotrexate (monotherapy)
Trial: 16484573
Drug: High-dose AGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose AGE (2.4 mL/d)
Trial: 16484573
Drug: Low-dose AGE
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose AGE (0.16 mL/d)
Trial: 7722710
Drug: Atole (high-energy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atole (high-energy, high-protein supplement: 163 kcal/682 kJ and 6.4 g protein per serving)
Trial: 7722710
Drug: Fresco (low-energy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresco (low-energy, no-protein supplement: 59 kcal/247 kJ per 180 mL)
Trial: 2126727
Drug: Active nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active nitroglycerin patches (10mg/24hrs)
Trial: 7237200
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally two hours pre-operatively
Trial: 7237200
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 0.3 M solution 30 ml orally
Trial: 7659199
Drug: Electroconvulsive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive treatment (ECT)
Trial: 23702050
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (8 weekly sessions of 90 minutes each)
Trial: 23702050
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) (8 weekly sessions of 90 minutes each)
Trial: 20425129
Drug: Intravenous cannula
RxNorm normalized name: CANNULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cannula stillete (IVCS)
Trial: 19536452
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg twice daily) and omeprazole (20 mg once daily) for 18 months
Trial: 11433128
Drug: Lisinopril 5mg
RxNorm normalized name: LISINOPRIL 5MG TAB
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril 5mg (low dose)
Trial: 9622936
Drug: Low Molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Molecular Weight Heparins (LMWH) at home followed by oral anticoagulant
Trial: 9622936
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin (UFH) in hospital followed by oral anticoagulant
Trial: 9773138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without lidocaine infusion
Trial: 2626338
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine mouthrinse, 15 ml, 3 times daily
Trial: 1107960
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ten units of regular insulin twice a day for five days
Trial: 26431124
Drug: Intraarticular facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular facet joint injections
Trial: 17110816
Drug: Intravenous glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glycine infusion
Trial: 11302905
Drug: Acid suppressing
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid suppressing drugs or specialist referral at general practitioner's discretion
Trial: 23765630
Drug: Netupitant 50
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netupitant 50 mg
Trial: 30576544
Drug: Netupitant 100
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netupitant 100 mg
Trial: 23765630
Drug: Netupitant 200
RxNorm normalized name: Netupitant
DrugBank: Netupitant (DB09048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netupitant 200 mg
Trial: 15118196
Drug: CordyMax Cs-4
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CordyMax Cs-4 (3 g/d)
Trial: 16700802
Drug: Eberconazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eberconazole 1% cream
Trial: 9571333
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (insulin therapy alone)
Trial: 29389170
Drug: Varenicline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg/day
Trial: 11165950
Drug: Risedronate 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 20 mg/day for 14 days, followed by placebo for 42 days
Trial: 11165950
Drug: Risedronate 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 20 mg/day for 14 days, followed by elemental calcium 1000 mg/day and placebo for 14 days, then by placebo for 28 days
Trial: 11165950
Drug: Risedronate 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 20 mg/day for 7 days, followed by elemental calcium 1000 mg/day and placebo for 21 days, then risedronate 20 mg/day for 7 days, and finally elemental calcium 1000 mg/day and placebo for 21 days
Trial: 2742099
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) administered intravenously 8 minutes before induction
Trial: 26618458
Drug: 3 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times injection with 4 cc dose
Trial: 22995453
Drug: No antifibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifibrinolytic agent or placebo (Control Group).
Trial: 17178496
Drug: Podophyllin resin
RxNorm normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Podophyllin resin (25%) together with acyclovir cream (5%)
Trial: 7512659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PSA and digital rectal examination
Trial: 18562773
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) supplementation (1 g/kg body weight)
Trial: 15799734
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% solution subconjunctivally